Drugs News and Research

RSS

Benzodiazepines associated with fatal pneumonia

Benzodiazepines are associated with an increased risk for developing pneumonia, as well as an increased risk for dying from pneumonia, research shows.

12 Dec 2012

AstraZeneca, Case Western Reserve initiate AZD5847 Phase 2a trial in TB

Case Western Reserve University School of Medicine and AstraZeneca, a global biopharmaceutical company, today announced the first patient enrolled in a Phase 2a trial to assess the effectiveness of AZD5847, a new test drug for patients with tuberculosis (TB), including patients with HIV co-infection.

12 Dec 2012

Researchers decipher mechanism by which anophelin binds to thrombin

An international project lead by the Molecular and Cell Biology Institute of Porto University with the participation of researchers from IMIM (Hospital del Mar Medical Research Institute) has, for the first time ever, deciphered the mechanism by which a substance called anophelin binds to an enzyme (thrombin) involved in the process of blood coagulation.

12 Dec 2012

Tiotropium benefits patients with chronic obstructive pulmonary disease

In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD), tiotropium bromide (tiotropium in brief) is one of the drugs available that can be prescribed for inhalation. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether tiotropium offers a perceptible advantage to patients compared to a dummy medication (placebo) and to other COPD drugs.

12 Dec 2012

Drugs for Neglected Diseases receives UNITAID grant for paediatric HIV programme

The Drugs for Neglected Diseases initiative welcomes the announcement by UNITAID to grant up to USD 17.3 million to the organization for its paediatric HIV programme.

12 Dec 2012

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.

12 Dec 2012

AC253 drug appears to restore memory in Alzheimer's brain cells

Medical researchers at the University of Alberta have discovered a drug intended for diabetes appears to restore memory in Alzheimer's brain cells.

11 Dec 2012

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Durata Therapeutics, Inc. today announced preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

11 Dec 2012

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Dementia is the umbrella term used to describe a number of neurodegenerative brain disorders that cause progressive changes in thinking abilities and behaviour. The kind of deficits experienced by individuals diagnosed with dementia depends on the location and severity of the pathology in the brain.

11 Dec 2012

Telestroke networks benefit hospital bank balances

Telestroke networks can increase the number of patients successfully discharged home while saving money for all hospitals involved, show US study results.

11 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Studies examine current treatment standards for patients with clotting disorders

Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes.

11 Dec 2012

Pomalidomide safe and effective in treating multiple myeloma

A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

SCOTUS agrees to hear 'pay-for-delay' drug case

The Supreme Court will hear arguments on the legality of drug companies paying their generic-making counterparts to keep generic drugs -- in this case, a testosterone gel -- off the market.

11 Dec 2012

Governments, donors should follow PMI model of testing drugs for quality

"[W]e are losing the global fight against bad medicines," and though "[s]ome progress is being made," the "problem is that ... crackdowns tend to focus on counterfeit drugs" while a "much bigger public health problem ... is substandard drugs that are the result of shoddy manufacturing and handling -- or perhaps worse, deliberate corner-cutting," Roger Bate, a resident scholar at the American Enterprise Institute, writes in an opinion piece in The Hill's "Congress Blog."

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

UNM study to understand why and how DNA repair mechanisms go awry in cancer cells

DNA, like houses and cars, needs ongoing maintenance. Rays of ultraviolet sunlight, chemical pollutants and normal biochemical processes in the cell can damage it. Cells routinely repair this damage before making proteins or copying DNA for cell division. The repairs are remarkably accurate in normal cells but cancer cells make far more mistakes in fixing their DNA.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Biogen Idec and Isis Pharmaceuticals, Inc. today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.

11 Dec 2012

Drugs News and Research

Benzodiazepines associated with fatal pneumonia

AstraZeneca, Case Western Reserve initiate AZD5847 Phase 2a trial in TB

Researchers decipher mechanism by which anophelin binds to thrombin

Tiotropium benefits patients with chronic obstructive pulmonary disease

Drugs for Neglected Diseases receives UNITAID grant for paediatric HIV programme

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

AC253 drug appears to restore memory in Alzheimer's brain cells

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Telestroke networks benefit hospital bank balances

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Studies examine current treatment standards for patients with clotting disorders

Pomalidomide safe and effective in treating multiple myeloma

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

SCOTUS agrees to hear 'pay-for-delay' drug case

Governments, donors should follow PMI model of testing drugs for quality

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

UNM study to understand why and how DNA repair mechanisms go awry in cancer cells

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News